MSC Therapy Shows Promise Despite Mixed Clinical Results
Review reveals safety of mesenchymal stem cell therapy but highlights efficacy challenges in clinical trials.
20 articles
Review reveals safety of mesenchymal stem cell therapy but highlights efficacy challenges in clinical trials.
Comprehensive review reveals how MSCs repair tissues and modulate immunity across multiple diseases, offering new therapeutic pathways.
A comprehensive 2025 review reveals how MSCs repair damaged livers through immunomodulation, anti-fibrotic action, and regenerative signaling.
New review consolidates MSC biology breakthroughs, clinical approvals, and the standardization hurdles still blocking broader therapeutic success.
A 2025 review maps preclinical and clinical evidence for MSC therapy in Alzheimer's, detailing mechanisms, limitations, and future directions.
Phase Ia/Ib dose-escalation trials reveal MSC therapy is safe in decompensated liver cirrhosis, with higher doses producing stronger immune rebalancing effects.
Combining mesenchymal stem cell transplantation with exercise may overcome key limitations of standalone therapy for sarcopenia.
Mesoblast licenses CAR technology to make its stem cell therapies smarter at finding inflamed tissue, targeting IBD and autoimmune disease.
Transplanted young muscle stem cells improved motor function and reduced anxiety in aged mice through enhanced blood vessel growth.
Human umbilical cord stem cells and their exosomes combat dexamethasone-induced muscle wasting via estrogen receptor pathways in mice and cell models.
A naturally occurring stem cell type called Muse cells shows early promise in homing to damaged tissue, differentiating widely, and avoiding immune rejection.
Beijing's 301 Hospital begins recruiting adults 50+ for the world's largest stem cell antiaging clinical trial using an already-approved therapy.
Engineered vesicles deliver healthy mitochondria to damaged brain vessels post-stroke, reprogramming metabolism and triggering angiogenesis in mice.
Review examines orthobiologics like stem cells and platelet-rich plasma for cartilage regeneration, revealing promising outcomes.
A rare stress-resilient cell type may solve the biggest failure in stem cell therapy: most injected cells never reach damaged tissue.
A dual human-primate trial finds donor MSC infusions are safe but do not establish chimerism or tolerance, and may trigger rejection-causing antibodies.
A rare stress-enduring stem cell subpopulation called Muse cells could solve regenerative medicine's biggest failures and slow tissue aging.
Dr. Matt Cook reveals breakthrough MUSE cells that home to damaged tissue 15x better than MSCs, plus peptide protocols and precision medicine advances.
Deramiocel slowed upper limb decline by 54% and preserved heart function in boys with Duchenne muscular dystrophy in a landmark phase III trial.
Comprehensive review reveals stem cell research advances alongside persistent challenges in clinical translation and regulation.